New Eye Tech Is Booming For Alcon, Stock Soars

Core Insights - Alcon Inc. reported third-quarter sales of $2.59 billion, a 6% year-over-year increase, slightly missing the consensus estimate of $2.60 billion [1] - The company achieved adjusted earnings of 79 cents, surpassing the consensus of 76 cents [2] Sales Performance - Surgical net sales reached $1.42 billion, reflecting a 6% increase on a reported basis and a 5% increase on a constant currency basis year over year [3] - Vision Care net sales totaled $1.2 billion, marking a 7% increase on a reported basis and a 5% increase on a constant currency basis [3] Operating Income and Margins - Core operating income was $523 million, representing a 4% increase, with a core operating margin of 20.20%, down 0.4 percentage points from the previous year [4] - The decrease in margin was attributed to tariffs, sales and marketing investments, and increased R&D spending, partially offset by manufacturing efficiencies and price increases [4] Future Outlook - Alcon affirmed its fiscal year 2025 adjusted earnings guidance of $3.05-$3.15, compared to the consensus of $3.06 [5] - The company maintained its 2025 sales guidance of $10.3 billion to $10.4 billion, against a consensus of $10.39 billion [5] - Core operating margin is expected to range between 19.5% and 20.5% [5] Stock Performance - Alcon shares increased by 4.91% to $81.15 at the time of publication [5]